Stock VIRX VIRACTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.8196 USD -0.17% Intraday chart for Viracta Therapeutics, Inc. -3.33% +43.79%
Apr. 15 Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial CI
Apr. 01 Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan CI

Evolution of the average Target Price on Viracta Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d3f8573ad5e63f91f.8BJ74DnJe4FlbwU7wTx82OUwA96QNjHuT4UsxPqFdgA.wlw21G-AC9AHPHINhQUGqNxlTqzeU1mtPbR19J-0PXPDVEKOTK0C6isYZg~622409e9aad4c87d512c10da0f12e5e0

Analyst Recommendations on Viracta Therapeutics, Inc.

RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk MT
HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating MT
RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating MT
Oppenheimer Adjusts Viracta Therapeutics Price Target to $16 From $14, Maintains Outperform Rating MT
RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk MT
History shows stocks can weather rate hike cycle RE
Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share MT
Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall MT
VIRACTA THERAPEUTICS : HC Wainwright Starts Viracta Therapeutics at Buy With $35 Price Target MT
VIRACTA THERAPEUTICS : SVB Leerink Initiates Viracta Therapeutics at Outperform With $18 Price Target MT
VIRACTA THERAPEUTICS : Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8196 USD
Average target price
7 USD
Spread / Average Target
+754.08%
High Price Target
13 USD
Spread / Highest target
+1,486.14%
Low Price Target
4 USD
Spread / Lowest Target
+388.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viracta Therapeutics, Inc.

RBC Capital Markets
HC Wainwright
Oppenheimer
SVB Leerink
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VIRX Stock
  4. Consensus Viracta Therapeutics, Inc.